In 1928, Alexander Fleming returned from a vacation to find that a petri dish of Staphylococcus bacteria he had left on his laboratory bench had been contaminated by a mold — Penicillium notatum. What caught his attention was not the mold itself but what surrounded it: a clear zone in the culture dish where the bacteria had died. Something the mold was secreting was killing bacteria.
Fleming published his observation in 1929, noting that the mold's exudate — which he called penicillin — inhibited bacterial growth. He could not stabilize or purify it at the time, and the discovery languished. It was not until Howard Florey and Ernst Chain at Oxford developed a way to purify penicillin in 1940-1941 that the clinical potential became clear. In 1942, the first patient was treated: an Oxford policeman named Albert Alexander, dying of a bacterial infection that had spread from a scratch. He began to improve dramatically on the new drug. Then the supply ran out — penicillin was still being produced in tiny quantities. Alexander died.
By 1944, large-scale production had been achieved, and penicillin was deployed to treat wounded Allied soldiers. A drug that had been a laboratory curiosity five years earlier was saving thousands of lives per week. The antibiotic era had begun.
The revolution penicillin initiated transformed medicine completely. Before antibiotics, bacterial infections were a leading cause of death: pneumonia, tuberculosis, sepsis, wound infections, childbed fever. After antibiotics, most of these became treatable. Surgery became immeasurably safer. Organ transplantation became possible. Cancer chemotherapy, which suppresses the immune system, became survivable.
Now the revolution is under threat. The same evolutionary mechanism that makes bacteria so adaptable — rapid reproduction combined with genetic mutation — is driving the spread of antibiotic resistance. The post-antibiotic future is not hypothetical; it is being documented in hospitals around the world, where infections that were routinely treatable two decades ago are now life-threatening.
"The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant." — Alexander Fleming, Nobel Prize lecture, 1945
Key Definitions
Antibiotic — A substance that kills bacteria or inhibits their growth, used clinically to treat bacterial infections. The term originally referred to compounds produced by microorganisms (like penicillin from mold), but now includes synthetic compounds as well. Not effective against viral, fungal, or parasitic infections.
Bactericidal — An antibiotic that kills bacteria directly (as opposed to merely stopping their growth). Examples: penicillins, cephalosporins, fluoroquinolones, aminoglycosides. Preferred for serious infections where rapid bacterial killing is critical.
Bacteriostatic — An antibiotic that inhibits bacterial reproduction without directly killing them, allowing the immune system to eliminate the static bacteria. Examples: tetracyclines, macrolides, sulfonamides. Generally adequate for mild-to-moderate infections in immunocompetent patients.
Minimum Inhibitory Concentration (MIC) — The lowest concentration of an antibiotic that prevents visible bacterial growth. The MIC is used to determine whether a bacterial strain is susceptible or resistant to a given antibiotic, and to guide dosing decisions.
Broad-spectrum antibiotic — An antibiotic effective against a wide range of bacteria, including both gram-positive and gram-negative organisms. Useful when the specific pathogen is unknown. Examples: amoxicillin-clavulanate, fluoroquinolones, carbapenems.
Narrow-spectrum antibiotic — An antibiotic effective against a limited range of bacterial species. Preferred when the specific pathogen is known, as it minimizes disruption to the body's normal microbiome and reduces selection pressure for resistance. Example: penicillin G against streptococcal infections.
Gram-positive bacteria — Bacteria with thick cell walls that stain blue-purple in the Gram staining procedure. Generally more susceptible to certain antibiotics. Examples: Staphylococcus, Streptococcus, Enterococcus.
Gram-negative bacteria — Bacteria with thin cell walls surrounded by an outer membrane that stains pink-red in Gram staining. The outer membrane provides additional protection against many antibiotics. Examples: Escherichia coli, Klebsiella, Pseudomonas, Neisseria.
Antibiotic resistance — The ability of bacteria to survive and reproduce in the presence of antibiotic concentrations that would normally kill or inhibit them. Can result from mutation, gene transfer, or efflux pumps that expel antibiotics from the bacterial cell.
Horizontal gene transfer — The transfer of genetic material between bacteria by mechanisms other than reproduction: conjugation (direct cell-to-cell transfer via pili), transduction (transfer via bacteriophage), or transformation (uptake of DNA from the environment). Resistance genes spread rapidly through bacterial populations via horizontal gene transfer.
ESKAPE pathogens — Six bacterial species that are the most clinically important antibiotic-resistant pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. The name also suggests that these pathogens can "escape" the effects of antibiotics.
Microbiome — The community of microorganisms living in and on the human body, particularly in the gut. Antibiotics disrupt the microbiome, which can have lasting effects on digestion, immune function, and mental health. Disruption of the gut microbiome by antibiotics also creates opportunities for resistant organisms or pathogens like Clostridioides difficile to establish themselves.
How Antibiotics Work: The Mechanisms
Different antibiotic classes disrupt different bacterial processes. Understanding these mechanisms explains both why they work and how bacteria become resistant.
1. Cell Wall Inhibitors: Penicillins and Cephalosporins
The cornerstone of antibiotic therapy for 80 years. Bacteria (unlike human cells) have rigid cell walls made of peptidoglycan — a mesh of sugar chains cross-linked by short peptides. This wall is essential: without it, the bacterium's internal pressure causes it to swell and burst.
Penicillins and cephalosporins (the beta-lactam antibiotics) work by inhibiting the enzymes (penicillin-binding proteins, PBPs) that build and repair the peptidoglycan wall. They do this by mimicking the substrate these enzymes normally act on — the terminal D-alanyl-D-alanine sequence in the peptidoglycan precursor — and binding irreversibly to the enzyme's active site.
When bacteria try to divide and must synthesize new cell wall, the inhibited PBPs cannot complete the wall. The wall develops gaps. Internal pressure causes rupture. The bacteria burst.
Why they're safe for humans: Human cells have no cell walls. Penicillins have no target in human cells and therefore have minimal direct toxicity. Allergic reactions (which affect 1-10% of patients) are the primary risk, not the drug mechanism itself.
How resistance develops: Many bacteria produce beta-lactamase enzymes that cleave the beta-lactam ring, inactivating the antibiotic. MRSA (methicillin-resistant Staphylococcus aureus) has acquired an altered PBP (PBP2a) that doesn't bind penicillins. Extended-spectrum beta-lactamases (ESBLs) in gram-negative bacteria can inactivate most penicillins and cephalosporins.
2. Protein Synthesis Inhibitors
Bacteria synthesize proteins using ribosomes — molecular machines that translate messenger RNA into protein. Bacterial ribosomes (70S, composed of 50S and 30S subunits) are structurally different from human ribosomes (80S). This difference allows several antibiotic classes to selectively inhibit bacterial but not human protein synthesis.
Aminoglycosides (gentamicin, streptomycin): Bind to the 30S ribosomal subunit, causing misreading of the genetic code — bacteria incorporate wrong amino acids into proteins. They are bactericidal and active against many gram-negative bacteria. Discovered from soil bacteria in the 1940s. Toxicity: kidney damage and hearing loss at high doses.
Tetracyclines (doxycycline, minocycline): Bind to the 30S subunit, blocking attachment of transfer RNA carrying the next amino acid — protein synthesis stalls. Bacteriostatic. Very broad spectrum. Used for Lyme disease, atypical pneumonias, acne.
Macrolides (azithromycin, erythromycin): Bind to the 50S subunit, blocking translocation — the ribosome cannot move along the mRNA to continue protein synthesis. Bacteriostatic. Widely used for respiratory infections and sexually transmitted infections.
Chloramphenicol: Binds the 50S subunit. Extremely effective broad-spectrum antibiotic — but causes rare, potentially fatal aplastic anemia (bone marrow failure) in humans, limiting its use to severe infections where other options are not available.
3. DNA Replication Inhibitors: Fluoroquinolones
Fluoroquinolones (ciprofloxacin, levofloxacin) target enzymes (DNA gyrase and topoisomerase IV) that bacteria use to manage DNA topology during replication and transcription. Bacterial DNA is circular and becomes tangled during replication; these enzymes introduce and repair breaks in DNA to allow unwinding. Fluoroquinolones trap these enzymes on cut DNA, preventing repair and causing lethal double-strand breaks.
Human cells use topoisomerase II for similar functions, but fluoroquinolones bind bacterial versions much more tightly than human ones — selective toxicity based on structural differences.
Resistance: Mutations in the target enzymes reduce fluoroquinolone binding. Efflux pumps (active exporters that pump antibiotics out of the bacterial cell) reduce intracellular concentrations. Fluoroquinolone resistance has spread widely, including in common pathogens like E. coli and Neisseria gonorrhoeae.
4. Cell Membrane Disruption: Polymyxins
Polymyxins (colistin, polymyxin B) are "last resort" antibiotics for gram-negative bacteria resistant to all other drugs. They interact with lipopolysaccharide in the outer membrane of gram-negative bacteria, disrupting membrane integrity and causing cell contents to leak out.
They are highly effective bactericides but nephrotoxic — kidney damage at therapeutic doses. Their toxicity limited their use for decades, but the emergence of carbapenem-resistant gram-negative bacteria (pan-resistant organisms with no other treatment options) has revived their clinical use.
Resistance to colistin, previously rare, has emerged and spread through horizontal gene transfer of the mcr gene — a modification of the bacterial outer membrane that reduces polymyxin binding. mcr has been found in bacteria worldwide.
Antibiotic Resistance: The Global Crisis
The Scale of the Problem
The Lancet published the first comprehensive global analysis of antibiotic resistance deaths in 2022, reporting:
- 1.27 million deaths directly attributable to drug-resistant infections in 2019
- 4.95 million deaths in which drug-resistant infection was a contributing cause
- Drug-resistant lower respiratory infections and bloodstream infections were the largest contributors
The WHO's 2019 list of antibiotic-resistant priority pathogens identified 12 families of bacteria posing the greatest threat, with carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and third-generation cephalosporin-resistant Enterobacteriaceae, in the critical priority tier.
| Priority | Organism | Key Resistance | Clinical Impact |
|---|---|---|---|
| Critical | Acinetobacter baumannii (carbapenem-resistant) | Nearly pan-resistant | ICU infections, very high mortality |
| Critical | Pseudomonas aeruginosa (carbapenem-resistant) | Intrinsically resistant + acquired | Pneumonia, bloodstream infections |
| Critical | Enterobacteriaceae (carbapenem-resistant) | ESBL, carbapenemases | UTIs, pneumonia, bloodstream |
| High | Enterococcus faecium (vancomycin-resistant, VRE) | Vancomycin resistance | Hospital infections |
| High | Staphylococcus aureus (MRSA) | Beta-lactam resistance | Skin, lung, bloodstream |
| High | Helicobacter pylori (clarithromycin-resistant) | Macrolide resistance | Peptic ulcer disease |
How Resistance Evolves and Spreads
Vertical transmission: A mutation in a single bacterium that confers resistance is inherited by all its descendants. With generation times of 20-30 minutes, a resistant mutant in a single bacterium can become millions in a few hours.
Horizontal gene transfer: Resistance genes on plasmids (small circular DNA molecules separate from the bacterial chromosome) can be transferred between bacteria of the same or different species. A resistance gene that evolved in one species can spread to unrelated pathogens rapidly. The mcr-1 colistin resistance gene, first identified in China in 2015, spread globally within two years.
Selection pressure: Antibiotic use kills susceptible bacteria and allows resistant ones to proliferate. The more antibiotics are used — in human medicine, veterinary medicine, and agricultural applications — the stronger the selection pressure for resistance. This is why antibiotic overuse is a direct cause of accelerating resistance.
"We face, in the not-too-distant future, a post-antibiotic era, in which many common infections will once again kill." — Dr. Margaret Chan, WHO Director-General (2012)
Why New Antibiotics Are Scarce
Since the 1980s, no major new antibiotic class has been developed. The pipeline for new antibiotics is critically thin for several reasons:
Economic incentives are weak: An effective antibiotic is taken for 7-14 days and then replaced when resistance develops. By contrast, a drug for diabetes, hypertension, or depression may be taken for decades. The return on investment for antibiotic development is far lower than for chronic disease drugs. Large pharmaceutical companies have largely exited antibiotic research.
Scientific challenges are severe: The "low-hanging fruit" — easy bacterial targets that drugs can inhibit — have been exploited. Identifying new antibiotic targets that bacteria haven't developed resistance mechanisms against, and finding compounds that selectively inhibit those targets without human toxicity, is genuinely difficult.
The resistance problem undermines investment: Even if a company invests billions to develop a new antibiotic, resistance may develop quickly, and clinicians should hold the new drug in reserve for last-resort use — dramatically limiting market size.
Fighting Resistance: What Can Be Done
Stewardship Programs
Antibiotic stewardship programs in hospitals and healthcare systems aim to optimize antibiotic use: prescribing the right antibiotic for the right indication at the right dose for the right duration. Studies consistently show that stewardship programs can reduce antibiotic use by 20-50% without worsening patient outcomes — and reduce rates of Clostridioides difficile infection and resistance emergence.
Agricultural Use
Approximately 70% of antibiotics used worldwide are given to livestock — not primarily to treat infections, but as growth promoters (low doses of antibiotics increase animal growth efficiency). This represents an enormous reservoir of selection pressure for resistance.
The European Union banned the use of antibiotics as growth promoters in 2006. The US phased out medically important antibiotics as growth promoters (without therapeutic justification) in 2017. But globally, agricultural antibiotic use continues to grow with increasing meat production in developing countries.
Diagnostic Improvements
A fundamental problem driving overuse is the difficulty of rapidly distinguishing bacterial from viral infections. A patient with a respiratory infection may have a cold (viral, antibiotics useless) or bacterial pneumonia (bacterial, antibiotics essential). Lacking a fast, cheap diagnostic, clinicians often prescribe antibiotics "just in case."
Rapid diagnostic tests — including PCR-based tests and point-of-care tests that can identify pathogens and resistance profiles within hours — are being developed and deployed. Better diagnostics could significantly reduce unnecessary antibiotic prescribing.
For related concepts, see how vaccines work, how evolution works, and how the immune system works.
References
- Murray, C. J. L., et al. (2022). Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
- Fleming, A. (1945). Nobel Prize Lecture: Penicillin. NobelPrize.org.
- Walsh, C. T. (2003). Antibiotics: Actions, Origins, Resistance. ASM Press.
- World Health Organization. (2019). Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. WHO.
- Liu, Y. Y., et al. (2016). Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China. The Lancet Infectious Diseases, 16(2), 161–168. https://doi.org/10.1016/S1473-3099(15)00424-7
- Ventola, C. L. (2015). The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics, 40(4), 277–283.
- Brown, E. D., & Wright, G. D. (2016). Antibacterial Drug Discovery in the Resistance Era. Nature, 529(7586), 336–343. https://doi.org/10.1038/nature17042
Frequently Asked Questions
How do antibiotics kill bacteria without harming human cells?
Antibiotics exploit differences between bacterial and human cells. Bacteria have cell walls; human cells don't — so penicillin-class antibiotics disrupt bacterial cell wall synthesis without affecting human cells. Bacteria have different ribosome structures (70S vs human 80S) — so some antibiotics inhibit bacterial ribosomes selectively. These structural differences are the basis for selective toxicity.
Why don't antibiotics work on viruses?
Antibiotics target bacterial structures and processes: cell walls, ribosomes, DNA replication enzymes. Viruses lack all of these — they are not cells, have no ribosomes, and use their host's cellular machinery rather than their own. Antiviral drugs exist but work through different mechanisms specific to viral replication.
What is antibiotic resistance and how does it develop?
Antibiotic resistance occurs when bacteria evolve mechanisms to survive antibiotic treatment. Resistance arises through mutation or acquisition of resistance genes from other bacteria. Antibiotic use selects for resistant variants — bacteria without resistance die; resistant ones survive and reproduce, spreading resistance. Overuse and misuse of antibiotics accelerates this evolution.
How serious is the antibiotic resistance crisis?
Very serious. Drug-resistant infections killed approximately 1.27 million people directly in 2019 (Lancet study) and contributed to approximately 4.95 million deaths. The WHO considers antimicrobial resistance one of the top global public health threats. Without effective antibiotics, routine surgeries, organ transplants, and cancer chemotherapy become far more dangerous.
Should you always finish your antibiotic course?
Traditional advice to 'finish the course' is now more nuanced. Completing a prescribed course ensures complete elimination of the infection. However, unnecessarily long courses can increase selection pressure for resistance. Current guidance: take antibiotics only when prescribed, follow the specific prescription, and discuss with your doctor if you feel better before finishing.
What are the most dangerous antibiotic-resistant bacteria?
The WHO's ESKAPE pathogens are the highest-priority drug-resistant threats: Enterococcus faecium, Staphylococcus aureus (including MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. Carbapenem-resistant Enterobacteriaceae (CRE) and extensively drug-resistant tuberculosis are particularly concerning.
How are new antibiotics being developed?
New antibiotic development has slowed dramatically due to low commercial incentives (antibiotics are taken for short periods, limiting revenue) and the scientific challenge of finding new targets. Approaches include: discovering new antibiotic classes from environmental bacteria, reviving older antibiotics with new formulations, developing resistance-breaking combination therapies, and phage therapy (using viruses that target bacteria).